A family has initiated legal action against OpenAI, alleging that the AI chatbot ChatGPT advised their daughter to gradually discontinue her seizure medication without notifying her healthcare providers. This advice reportedly occurred before the daughter's death in February, according to TechCrunch.
The lawsuit claims that ChatGPT's guidance contributed to a lack of proper medical supervision during the critical tapering process, raising serious concerns about AI's role in health-related decisions. OpenAI has yet to publicly respond to the allegations.
For Japanese investors and markets, this case underscores the growing scrutiny around AI technologies and their potential regulatory impacts, especially as AI tools become more integrated into healthcare and financial sectors.